Elijah Stommel | Toxicology | Best Researcher Award

Posted on by sciencefather

Dr. Elijah Stommel | Toxicology | Best Researcher Award

Dr. Elijah W. Stommel is a distinguished neurologist born in Hamilton, Bermuda 🌊, currently serving as Professor of Neurology at the Geisel School of Medicine at Dartmouth 🧠, renowned for his clinical expertise, pioneering ALS research, and dedication to patient-centered care 💡; his prolific academic journey, consulting roles, and leadership in rare disease research reflect decades of unwavering service to neurology 🏥, academia 📚, and public health advocacy 🧬.

Profile

Education 🎓

Dr. Stommel holds an M.D. (1987) and a Ph.D. in Physiology (1984) from Boston University School of Medicine 🎓; he earned a B.A. with High Honors in Music from Bowdoin College 🎵 (1977), pursued advanced coursework at MIT 🏛️, and honed his research skills as a Research Assistant at the Marine Biological Laboratory in Woods Hole 🔬 — blending physiology, neurology, and music to form a truly interdisciplinary academic foundation 📘.

Experience 👨‍🏫

With over three decades in clinical neurology 🧠, Dr. Stommel progressed from Chief Resident at Dartmouth-Hitchcock (1990-91) to Professor of Neurology (2013–present) 👨‍🏫; he has served as Staff Neurologist at Dartmouth-Hitchcock Clinic since 1991 🏥, held multiple consultant roles across Vermont and New Hampshire 🗺️, and co-directs the Electromyography Lab ⚡, establishing himself as a trusted educator, clinician, and research mentor in both academic and hospital environments 🌟.

Awards & Recognitions 🏅

Dr. Stommel’s commitment to humanism and excellence in neurology earned him a nomination for the prestigious Tow Humanism in Medicine Award 🏆 (2011); he is a Fellow of the American Academy of Neurology 🎖️ and holds long-standing certifications in Electrodiagnostic Medicine and Neurology 🧠, complemented by leadership roles on numerous committees advancing research ethics, clinical trials, and medical education 📋💡.

Research Interests 🔬

Dr. Stommel’s research revolves around neurodegenerative diseases, especially ALS 🧬, exploring environmental toxins 🌿, nanotechnology 🧪, and biomarkers 🔍 to advance diagnostics and therapeutics; as an active reviewer and editor for journals like Nature Nanotechnology, Frontiers in Neurology, and Molecular Neurobiology 🧠, he continually shapes scientific discourse while his collaborative work with global ALS consortia helps identify novel causal pathways and treatment avenues 🌍💡.

Publications

Yuanyuan Li | Movement Disorder | Best Researcher Award

Posted on by sciencefather

Dr. Yuanyuan Li | Movement Disorder | Best Researcher Award

🧠 Dr. Yuanyuan Li is a dedicated neurologist and researcher specializing in neurodegenerative diseases, particularly Parkinson’s disease and REM sleep behavior disorder. She obtained her Ph.D. in Neurology from Shanghai Jiao Tong University School of Medicine and has been actively involved in cutting-edge research at Ruijin Hospital’s Department of Neurology. As a project leader, she has explored the role of α-synuclein in dopaminergic neurons, investigating its transport pathways and impact on cell viability. Dr. Li has authored multiple high-impact publications in renowned journals such as Neurology and J Neuroinflammation. Her work has contributed significantly to understanding the early biomarkers of neurodegenerative disorders. She has received prestigious awards, including the National Scholarship for Doctoral Students and the Outstanding Graduate Award from Shanghai Jiao Tong University. With numerous conference presentations and accolades, Dr. Li continues to drive forward advancements in neurodegenerative disease research. ✨📚

Profile

Education 🎓

🎓 Dr. Yuanyuan Li completed her Ph.D. in Neurology at Shanghai Jiao Tong University School of Medicine, where she focused on neurodegenerative diseases, particularly Parkinson’s disease and REM sleep behavior disorder. Her doctoral research emphasized the role of α-synuclein in dopaminergic neurons, uncovering its impact on neurodegeneration. Throughout her academic journey, Dr. Li consistently demonstrated excellence, earning the First-Class Academic Scholarship and the Meritorious Student Award. She was recognized as an Outstanding Graduate and received the prestigious National Scholarship for Doctoral Students. Beyond coursework, she actively engaged in translational research, bridging laboratory findings with clinical applications. Her education has provided a strong foundation in neurobiology, molecular neuroscience, and clinical neurology. With a passion for uncovering early biomarkers of neurodegeneration, Dr. Li’s educational background has shaped her into a leading researcher in the field. 📖🧬

Experience 👨‍🏫

Dr. Yuanyuan Li has extensive research experience at Ruijin Hospital’s Department of Neurology, affiliated with Shanghai Jiao Tong University School of Medicine. As a principal investigator, she led the Shanghai Jiao Tong University Doctoral Innovation Fund project, studying α-synuclein’s transport mechanisms in dopaminergic neurons and its effects on cell viability. Her expertise spans biomarker discovery, neuroinflammation, and disease progression in neurodegenerative disorders. She has collaborated on numerous high-impact studies published in Neurology, J Neuroinflammation, and NPJ Parkinson’s Disease. Dr. Li has also presented her findings at major conferences, including the National Neurology Conference and the Oriental Neurology Conference. Her experience in both basic and clinical research allows her to bridge the gap between laboratory discoveries and patient applications, advancing diagnostic and therapeutic strategies for Parkinson’s disease and related disorders. 🏥🧠

Awards & Recognitions 🏅

Dr. Yuanyuan Li has received numerous prestigious awards for her contributions to neurology and neuroscience research. She was awarded the National Scholarship for Doctoral Students, recognizing her academic excellence and groundbreaking research. She also received the Outstanding Graduate Award and the Meritorious Student Award from Shanghai Jiao Tong University. Her outstanding academic performance earned her the First-Class Academic Scholarship, demonstrating her dedication to advancing neurological research. Dr. Li has been recognized for her contributions at major conferences, winning the “Excellent Paper Presentation” award at the Oriental Neurology Conference. Additionally, she secured First Prize for Poster Presentation at the “Bo Ji Yi Yuan” Academic Forum. Her accolades reflect her commitment to advancing our understanding of neurodegenerative diseases, particularly Parkinson’s disease. These honors highlight her as a rising star in the field of neurology. 🏅📜

Research Interests 🔬

🧪 Dr. Yuanyuan Li’s research focuses on neurodegenerative diseases, with an emphasis on Parkinson’s disease, REM sleep behavior disorder (RBD), and α-synuclein pathology. Her work explores the molecular mechanisms driving these disorders, particularly the role of α-synuclein in dopaminergic neurons, its transport pathways, and its impact on cell viability. She has also investigated immune biomarkers, neuroinflammation, and genetic variants associated with Parkinson’s progression. Dr. Li’s studies have contributed to identifying predictive markers for early-stage neurodegenerative diseases, aiding in early diagnosis and potential therapeutic interventions. Through her publications in top journals like Neurology, J Neuroinflammation, and NPJ Parkinson’s Disease, she has advanced knowledge in the field. Her work integrates clinical and experimental neuroscience, bridging gaps between laboratory findings and real-world applications. Dr. Li’s research continues to shape the understanding of neurodegenerative disorders and their early detection. 🧬🔍

 

4Publications 

  • Gene Polymorphisms of Parkinson’s Disease Risk Locus and Idiopathic REM Sleep Behavior Disorder

    Biomedicines
    2025-03-24 | Journal article
    DOI: 10.3390/biomedicines13040788
    CONTRIBUTORS: Min Zhong; Yang Jiao; Aonan Zhao; Mengyue Niu; Jinjun Ran; Jun Liu; Yuanyuan Li

  • Understanding Causal Relationships Between Imaging-Derived Phenotypes and Parkinson’s Disease: A Mendelian Randomization and Observational Study

    Biomedicines
    2025-03-18 | Journal article
    DOI: 10.3390/biomedicines13030747
    CONTRIBUTORS: Yichi Zhang; Min Zhong; Zhao Yang; Xiaojin Wang; Zhongxun Dong; Liche Zhou; Qianyi Yin; Bingshun Wang; Jun Liu; Yuanyuan Li et al.

  • Understanding Causal Relationships between Imaging-Derived Phenotypes and Parkinson’s Disease: A Mendelian Randomization and Observational Study

    2025-02-05 | Preprint
    DOI: 10.20944/preprints202502.0350.v1
    CONTRIBUTORS: Yichi Zhang; Min Zhong; Zhao Yang; Xiaojin Wang; Zhongxun Dong; Liche Zhou; Qianyi Yin; Bingshun Wang; Jun Liu; Yuanyuan Li et al.

  • Network disruption based on multi-modal EEG-MRI in α-synucleinopathies

    Frontiers in Neurology
    2024 | Journal article
    DOI: 10.3389/FNEUR.2024.1442851
    WOSUID: WOS:001304283700001
    CONTRIBUTORS: Wang, Chunyi; Hu, Jiajia; Li, Puyu; Zhang, Ming; Zhou, Liche; Luo, Ningdi; Zhu, Xue; Yin, Qianyi; Zhong, Min; Zhou, Xinyi et al.

PİNAR ERKEKOGLU | Neurotoxicology | Best Researcher Award

Posted on by sciencefather

Prof. PİNAR ERKEKOGLU | Neurotoxicology | Best Researcher Award

Prof. Dr. Pınar Erkekoğlu is a distinguished academician and toxicologist at Hacettepe University, serving as Head of the Department of Pharmaceutical Toxicology and Department of Vaccine Technology. She holds a PhD in toxicology (2009) and became a European Registered Toxicologist (ERT) in 2014. She conducted research at Joseph Fourier University, CEA/INAC/LAN, and completed her postdoctoral studies at MIT (2011-2013). With over 200 scientific publications, 10 edited books, and 15 book chapters, her work spans toxicology, neurotoxicology, and vaccinology. Her h-index is 34, with 107 SCI-indexed papers and numerous collaborations.

Profile

Education 🎓

Prof. Erkekoğlu earned her Pharmacy degree from Hacettepe University and a PhD in toxicology (2009). She gained international research experience at Joseph Fourier University and CEA/INAC/LAN during her doctorate. In 2011-2013, she pursued postdoctoral research at MIT, specializing in toxicology and environmental sciences. Recognized for her expertise, she became a European Registered Toxicologist (ERT) in 2014.

Experience 👨‍🏫

Prof. Erkekoğlu has extensive experience in toxicology, environmental sciences, and vaccinology. She is the Head of Pharmaceutical Toxicology and Vaccine Technology at Hacettepe University. She has worked at MIT, Joseph Fourier University, and CEA/INAC/LAN. With 49 research projects, 4 industry consultancies, and 12 collaborations, she has contributed significantly to toxicological sciences.

Awards & Recognitions 🏅

Prof. Erkekoğlu has received numerous awards, including Best Researcher and Women Researcher Awards. She is recognized internationally for her contributions to toxicology, neurotoxicology, and vaccine technology. She has served as an editor for scientific books, peer-reviewed journals, and major toxicology conferences.

Research Interests 🔬

Her research encompasses neurotoxicology, endocrine disruption, environmental toxicology, and vaccinology. She has published 107 SCI-indexed papers and 161 documents in Scopus across pharmacology, medicine, and environmental sciences. Her work explores the toxic effects of chemicals on human health and vaccine development.

Publications 

  • Prepubertal phthalate exposure can cause histopathological alterations, DNA methylation and histone acetylation changes in rat brain

    Toxicology and Industrial Health
    2025-03 | Journal article
    DOI: 10.1177/07482337251315212
    CONTRIBUTORS: Seyda Koc; Ekin Erdogmus; Ozlem Bozdemir; Deniz Ozkan-Vardar; Unzile Yaman; Pınar
    Erkekoglu; Naciye Dilara Zeybek; Belma Kocer-Gumusel

  • The ameliorative potential of metformin against aluminum‐induced neurotoxicity: Insights from in vitro studies

    Journal of Applied Toxicology
    2025-02 | Journal article
    DOI: 10.1002/jat.4695
    CONTRIBUTORS: Sonia Sanajou; Anil Yirün; Göksun Demirel; Pinar Erkekoğlu; Gönül Şahin; Terken Baydar

  • Unveiling connections: bisphenol A and vitamin D dynamics in breast milk among healthy lactating mothers

    International Journal of Environmental Health Research
    2024-10-10 | Journal article
    DOI: 10.1080/09603123.2024.2412118
    CONTRIBUTORS: Esra Cinkilli Aktağ; Sıddika Songül Yalçin; Anıl Yіrün; Aylin Balci Özyurt; Pınar Erkekoğlu

  • Bisphenol derivatives in cord blood and association between thyroid hormones and potential exposure sources

    International Journal of Environmental Health Research
    2024-08-02 | Journal article
    DOI: 10.1080/09603123.2023.2286016
    CONTRIBUTORS: Merve Buke Sahin; Murat Cagan; Anıl Yirun; Aylin Balcı Ozyurt; Selinay Basak Erdemli Kose; Irem Iyigun; Melda Celik; Ozgur Ozyuncu; Pınar Erkekoglu; Cavit Isik Yavuz

  • Comparative in silico and in vitro evaluation of possible toxic effects of bisphenol derivatives in HepG2 cells

    Toxicology Research
    2024-07-01 | Journal article
    DOI: 10.1093/toxres/tfae127
    CONTRIBUTORS: Aylin Balci-Ozyurt; Anıl Yirun; Deniz Arca Cakır; İbrahim Ozcelik; Merve Bacanli; Gizem Ozkemahli; Suna Sabuncuoglu; Nursen Basaran; Pınar Erkekogl

 

Aynur Müdüroğlu Kırmızıbekmez | Neurodevelopmental Disorders | Best Researcher Award

Posted on by sciencefather

Prof Dr. Aynur Müdüroğlu Kırmızıbekmez | Neurodevelopmental Disorders | Best Researcher Award

Asst. Prof. Aynur Müdüroğlu Kırmızıbekmez is a neuroscientist at İstanbul Nişantaşı University, specializing in neurodegenerative diseases, neuroprotection, and the gut-brain axis. She completed her Ph.D. in Neuroscience at Istanbul University in 2013 and has been a faculty member since 2014. Her research spans Alzheimer’s, autism, and Parkinson’s disease, focusing on stem cell therapies and functional foods for cognitive enhancement. She has led TÜSEB-approved projects and holds patents on bioactive functional foods. Aynur teaches Neurology, Cognitive Neurophysiology, and Industrial Biotechnology. She actively contributes to cutting-edge innovations, particularly in prebiotic-microbiota interactions.

Profile

Education 🎓

Aynur Müdüroğlu Kırmızıbekmez earned her Ph.D. in Neuroscience from Istanbul University in 2013. Her academic journey emphasized neurobiology, neurodegenerative disease mechanisms, and innovative therapeutic strategies. Her doctoral research focused on neuroprotective compounds in Alzheimer’s disease. Before her Ph.D., she pursued studies in molecular biology and biotechnology, refining her expertise in cellular neuroscience. Throughout her education, she collaborated on interdisciplinary projects, integrating neurophysiology with pharmacological advancements. Her postdoctoral research extended into translational neuroscience, bridging laboratory findings with clinical applications. Aynur’s academic foundation laid the groundwork for her extensive research on cognitive function, stem cell therapy, and the gut-brain axis.

Experience 👨‍🏫

With over a decade of experience, Aynur Müdüroğlu Kırmızıbekmez has been an Assistant Professor at İstanbul Nişantaşı University since 2014. She has led multiple national and international neuroscience projects, including TÜSEB-approved research on Parkinson’s and Alzheimer’s diseases. Aynur has played a pivotal role in developing functional foods aimed at cognitive enhancement and has secured patents for novel bioactive compounds. She actively collaborates with industry and academia, integrating neuroscience with biotechnology. Her teaching portfolio includes Neurology, Cognitive Neurophysiology, and Industrial Biotechnology. She has also mentored numerous graduate students in neuropharmacology and neurodegenerative research.

Research Interests 🔬

Aynur Müdüroğlu Kırmızıbekmez’s research focuses on neurodegenerative diseases, neuroprotection, and the gut-brain axis. She explores innovative therapies for Alzheimer’s, Parkinson’s, and autism, with a strong emphasis on stem cell applications. Her work investigates the neuroprotective potential of bioactive compounds and functional foods, aiming to enhance cognitive function. She has pioneered research on the microbiota-brain relationship, particularly the role of prebiotics in neurodegeneration. Aynur’s projects also include SNP-based qPCR diagnostic tools for Alzheimer’s risk assessment. Through interdisciplinary collaborations, she integrates neuroscience with biotechnology, advancing the understanding of cognitive disorders and potential therapeutic interventions.

Awards & Recognitions 🏅

Aynur Müdüroğlu Kırmızıbekmez has received multiple awards for her contributions to neuroscience, including national research grants and innovation awards for her work on functional foods for neuroprotection. She was honored by TÜSEB for her groundbreaking research in stem cell therapy for Parkinson’s disease. Her patented functional chocolate enriched with bioactive compounds received recognition for its cognitive benefits. Aynur has also been awarded project grants from TÜBİTAK for her research on neurodegeneration. She has been invited as a keynote speaker at international neuroscience conferences and has been recognized for her contributions to cognitive science.

Publications 📚

  • Attila Altunel, Aynur Muduroglu-Kirmizibekmez, Alparslan Onder, Ozlem Altunel, Ali
    Sever, Ihsan Kara, Efficacy of ACTH therapy in children with Landau-Kleffner Syndrome
    and Autism Spectrum Disorder: A retrospective analysis, Epilepsy & Behavior,Vol
    165,2025,110308, https://doi.org/10.1016/j.yebeh.2025.11030
  • Muduroglu-Kirmizibekmez A, Cati C, Onder A, Aydin S, Kara I. Investigation of the acute
    impact of rosemary consumption on brain activity in healthy volunteers. Nutr
    Neurosci. 2024 Jul 6:1-12. doi: 10.1080/1028415X.2024.2370729. Epub ahead of print.
    PMID: 38970803.
  • Biliz Y, Hasdemir B, Başpınar Küçük H, Zaim M, Şentürk AM, Müdüroğlu Kırmızıbekmez
    A, Kara İ. Novel N-Acyl Hydrazone Compounds as Promising Anticancer Agents:
    Synthesis and Molecular Docking Studies. ACS Omega. 2023 May 20;8(22):20073-
    20084. doi: 10.1021/acsomega.3c02361. PMID: 37305237; PMCID: PMC10249086.
  • Aydin S, Erözden AA, Tavşanlı N, Müdüroğlu A, Çalışkan M, Kara İ. Anthocyanin
    Addition to Kefir: Metagenomic Analysis of Microbial Community Structure. Curr
    Microbiol. 2022 Sep 20;79(11):327. doi: 10.1007/s00284-022-03017-x. PMID:
    36125585
  • Altunel Atilla, Müdüroğlu Kirmizibekmez Aynur, Altunel Emine Özlem (2022).
    Hypsarrhythmia Paroxysm Intensities that Initiate and Render Physical & Mental
    Retardation Irreversible in West Syndrome. International Journal of Neuroscience,
    DOI: 10.1080/00207454.2022.2078208 (Publication No: 7685958)

Carmela Conte | Neurodegenerative diseases | Best Researcher Award

Posted on by sciencefather

Prof Dr. Carmela Conte | Neurodegenerative diseases | Best Researcher Award

 

Profile

Education

Carmela Conte obtained her Master’s degree in Biological Sciences from the University of Perugia on November 3, 1994. She then pursued a Ph.D. in Medical Embryology through a joint program between the Universities of Perugia and Ferrara, completing it between December 30, 1996, and January 19, 2000. Following this, she specialized in Chemistry and Food Technology at the University of Perugia, earning her specialization between November 1, 2000, and November 1, 2002. Most recently, on September 29, 2023, she received National Habilitation as an Associate Professor in Biochemistry. She currently serves as an Aggregate Professor in her field.

Work experience

Since September 7, 2007, Carmela Conte has been serving as an Aggregate Professor in Biochemistry at the University of Perugia, where she teaches courses in General and Systematic Biochemistry, Medical Applied Biochemistry, and Molecular Biology. In addition to her teaching responsibilities, she participated in a Teaching and Training Mobility Program at VUMC Medical University of Amsterdam from June 24 to July 5, 2019, where she worked on a research project investigating the role of Toll-like receptors in Parkinson’s disease. She has been a member of the European Society for Neurochemistry since 2007 and, since March 17, 2022, has also been affiliated with the International Parkinson and Movement Disorder Society.

Research Activity

Carmela Conte’s research focuses on neurodegenerative diseases, with particular emphasis on animal models, signal transduction, molecular biology, and cell biology. Her specific research topics include the role of Toll-like receptors in Parkinson’s disease, neuroinflammation, synucleinopathies, oxidative stress, and Parkinson’s disease. Since September 7, 2007, she has been actively involved in editorial work, serving as a Reviewer Editor for Frontiers in Neuroscience (Neurodegeneration section) and as an ad hoc reviewer for several journals, including Amino Acids, The Cerebellum, Free Radical Research, Biomolecules, PLOS One, Experimental Gerontology, Molecules, Cells, Neurochemical Research, Neuroscience, Pharmacological Reports, International Journal of Molecular Sciences, Viruses, and the Journal of Biotechnology. Additionally, she has been a Guest Editor for Molecules and Cells, overseeing special issues and topic collections on neurodegenerative diseases. She has presented her research at numerous scientific meetings and conferences, including the 2009 Meeting of the European Society for Neurochemistry in Leipzig, the 2019 European Biotechnology Congress in Valencia, the 2021 European Biotechnology Congress in Sofia, the 2022 National Meeting of the Sphingolipid Club, and the 2023 Meeting of Parkinson’s Disease and Movement Disorders, where she discussed findings related to Toll-like receptor 4, alpha-synuclein accumulation, and sphingomyelinase activity in Parkinson’s disease models.

Publication

Suleyman Yildizdal | Craniosynostosis | Best Researcher Award

Posted on by sciencefather

Dr. Suleyman Yildizdal | Craniosynostosis | Best Researcher Award

 

 

Profile

Education

He completed his education at Org. Kenan Evren School from 2000 to 2008, followed by Gaziantep Anadolu High School from 2008 to 2012. He then pursued his medical training at Hacettepe University Faculty of Medicine from 2012 to 2018. After earning his medical degree, he continued his specialization in Plastic, Reconstructive, and Aesthetic Surgery as a resident at Hacettepe University Faculty of Medicine from November 2018 to February 2024. In April 2024, he joined Ankara Research and Training Hospital, where he continues to work in the Department of Plastic, Reconstructive, and Aesthetic Surgery.

 

Work experience

He has participated in various courses and workshops to enhance his expertise in plastic, reconstructive, and aesthetic surgery. He attended the Resident Ethics Course at Hacettepe University’s Department of History of Medicine and Medical Ethics on January 10-11, 2019. He also completed the 5th Basic Residency School organized by the Turkish Society of Plastic, Reconstructive, and Aesthetic Surgery in Bolu, Turkey, from January 22-25, 2020. Further advancing his skills, he took part in the 15th Advanced Residency School in Antalya, Turkey, from April 20-24, 2023. Additionally, he attended the 1st Cadaver Course of Craniofacial Anomaly and Maxillofacial Surgery at Hacettepe University on September 3-4, 2022, and the 1st Cadaver Course of Orthognathic Surgery at Koc University Hospital in Istanbul, Turkey, on September 7-8, 2022.

In addition to his clinical and surgical training, he has contributed to academic literature by co-authoring book chapters. He co-wrote Age-Related Changes in Trunk Aesthetics in Beauty, Aging, and Anti-Aging (1st ed., Elsevier, 2022) alongside G. G. Üstün and S. Yıldızdal. He also contributed to Dudak ve Damak Yarıkları Hacettepe Ekip Yaklaşım, co-authoring “Apert and Crouzon Syndrome” with İbrahim Vargel.

Awards

He has achieved remarkable academic success, securing 16th place in the National Examination for Specialty in Medicine among over 18,000 participants. Additionally, he ranked 571st in the National Student Selection and Placement Examination out of more than 2 million candidates.

He has actively participated in national meetings within his field, contributing to discussions and advancements in plastic, reconstructive, and aesthetic surgery. He attended the 41st National Turkish Plastic Reconstructive and Aesthetic Surgery Meeting in Samsun, Turkey, from October 26-30, 2019. He also participated in the National Turkish Plastic Reconstructive and Aesthetic Surgery Eastern Mediterranean Meeting on Cleft Lip and Palate, held in Gaziantep, Turkey, from February 7-9, 2020. Furthermore, he attended the 43rd National Turkish Plastic Reconstructive and Aesthetic Surgery Meeting in Antalya, Turkey, from November 10-14, 2021.

 

Publication

Michal Schwartz | Neurodegenerative diseases | Best Researcher Award

Posted on by sciencefather

Prof Dr. Michal Schwartz | Neurodegenerative diseases | Best Researcher Award

Michal Schwartz (born 1 January 1950) is a professor of neuroimmunology at the Weizmann Institute of Science. She is active in the field of neurodegenerative diseases, particularly utilizing the immune system to help the brain fight terminal neurodegenerative brain diseases, such as Alzheimer’s disease and dementia.[3][1]

Schwartz’s studies have shown that the immune system supports a healthy brain’s function and is vital for healing and protecting the brain in case of injury or disease.[4]

Schwartz coined the term protective autoimmunity[5] and discovered roles for immune cells in repair and neurogenesis. She has been the elected chair of the International Society of Neuroimmunology (ISNI) since 2016.[6]

In 2023 Schwartz received the honorary Israel Prize for Life Sciences.

 

Profile

Education

Schwartz gained her Bachelor of Science in chemistry at the Hebrew University of Jerusalem in 1972. She received her Ph.D in Immunology in 1977 at the Weizmann Institute of Science, where she would later spend the majority of her career. She also spent time at the University of Michigan, Ann Arbor, researching nerve regeneration.[when?

 

Work experience

At the Weizmann Institute, she progressed from senior scientist in the Department of Neurobiology to full professor in 1998, and was then awarded the Maurice and Ilse Katz Professorial Chair in Neuroimmunology in 2016.[7] Schwartz’s work in neuroimmunology has encompassed a wide range of pathologies in the central nervous system (CNS), including injury, neurodegeneration, mental dysfunction, and aging. She coined the term protective autoimmunity and demonstrated the role of immune cells such as macrophages and T cells in spinal cord repair. She also identified specific brain areas for ‘cross talk’ between the CNS and the immune system. This cross-talk is important for recruiting immune cells and maintaining a healthy brain, and the disruption of this cross-talk can play a role in brain aging and neurodegenerative disease. She also showed this role in pregnancy and fetal brain development, where immune disruption in the mother can be linked to neurodevelopmental disorders in their children. Another focus of her work has been on repurposing cancer immunotherapies such as PD-1 blockers to treat neurodegenerative disorders, such as Alzheimer’s disease.

Macrophages

The Schwartz team discovered that bone marrow-derived macrophages are needed for central nervous system (CNS) repair. The brain-resident myeloid cells (the microglia), and infiltrating monocyte-derived macrophages are not redundant populations, despite their myeloid phenotype, and display distinct functions in resolution of brain inflammation.[8][9][10]

Autoimmunity

In her research, Schwartz discovered that the ability to cope with sterile CNS injuries requires support in the form of an adaptive immune response mediated by CD4+ T cells that recognize CNS antigens. She coined the concept of protective autoimmunity, to distinguish this response from autoimmune disease, in which the anti-self response escapes control. Over the years, it became clear that adaptive immunity is needed to facilitate the recruitment of immunoregulatory cells, including bone marrow-derived macrophages and FoxP3 regulatory T cells, though the balance between regulatory T cells and effector memory cells is different in the periphery versus the brain.[11][12][13]

Brain Homeostasis

Schwartz’s team discovered the role of adaptive systemic immune cells, and specifically T cells recognizing brain antigens (Protective autoimmune T cells), in supporting the cognitive capacity of the healthy brain, for lifelong neurogenesis, and functional brain plasticity. These observations paved the way for numerous additional discoveries in which the brain-immune axis was described.[14][15][16]

The Choroid Plexus

Schwartz’s team identified the brain’s choroid plexus (CP) within the blood-cerebrospinal fluid barrier as an immunological interface between the brain and the immune system. It serves as a niche that hosts immune cells, and as a physiological entry gate for leukocytes. Focusing on this unique niche within the brain led the Schwartz group to propose that IFN-γ holds the key to regulating CP gateway activity. Her team further showed that in brain aging and neurodegenerative diseases (studied using both mouse models and human samples), dysfunction of this interface is determined both by signals originating in the brain, and signals from the aged immune system, which led to the identification of Type-I Interferon (IFN-I) at the CP as a negative player, affecting the fate of the aging brain in general, and of microglia, in particular. A similar IFN-I signature at the CP was subsequently discovered by others in Alzheimer’s disease and in the postmortem brains of infected patients who died from COVID-19.[17][14][10]

Immunotherapy

The discovery that adaptive immunity plays a key role in brain function and repair, the need for bone marrow-derived macrophages to resolve local brain inflammation, the fact that Alzheimer’s disease (AD) and all forms of dementia are mainly age-related diseases, and the fact that the immune system is particularly affected by aging all led Schwartz to propose a new treatment for combating dementias. Schwartz suggested empowering systemic immunity, using a form of immunotherapy by modestly blocking the inhibitory immune checkpoint PD1/PD-L1 pathway.[citation needed] This treatment drives an immune-dependent cascade of events, that allows the harnessing of bone marrow-derived macrophages and regulatory T cells to help clear toxic factors from the diseased brain, and to arrest the local inflammation, thereby providing a comprehensive multi-factorial therapy through modification of multiple elements that go awry in AD. Schwartz’s patents for developing such immunotherapy for AD are licensed to a small Biopharma company, Immunobrain Checkpoint. The company is awaiting a clinical trial in AD patients, supported in part by the National Institute of Aging, the US National Institutes of Health, and The Alzheimer’s Association.[18][19][20][21][22][23]

Publication

1. Rachmian N, Medina S, Cherqui U, Akiva H, Deitch D, Edilbi D, Croese T, Salame T, Peralta Ramos
J, Cahalon L, Krizhanovsky V, Schwartz M. 2024. Senescent microglia conserved in aging and
Alzheimer’s disease exhibit elevated TREM2 protein levels. Nat Neurosci 27: 1116-24
2. Tsitsou-Kampeli A, Suzzi S, Kenigsbuch M, Satomi A, Strobelt R, Singer O, Feldmesser E, Purnapatre
M, Colaiuta SP, David E, Cahalon L, Hahn O, Wyss-Coray T, Shaul Y, Amit I, Schwartz M. 2023.
Cholesterol 24-hydroxylase at the choroid plexus contributes to brain immune homeostasis. Cell Rep
Med: 101278
3. Suzzi, S. Croese T., Ravid A., Gold O., Clark A., Medina A., Kitsberg D., Adam M., Vernon K., Kohnert
E., Shapira I., Malitsky S., Itkin M., Brandis A., Mehlman T., Salame T., Colaiuta S., Cahalon L.,Slyper
M., Greka A., Habib N., Schwartz M. 2023. N-acetylneuraminic acid links immune exhaustion and
accelerated memory deficit in diet-induced obese Alzheimer’s disease mouse model 2023. Nat. Commun.
14:1293.
4. Kenigsbuch M, Bost P, Halevi S, Chang Y, Chen S, Ma Q, Hajbi R, Schwikowski B, Bodenmiller B, Fu
H, Schwartz M*, Amit I* (equal contribution, and corresponding authors). 2022. A shared diseaseassociated oligodendrocyte signature among multiple CNS pathologies. Nat Neurosci 25: 876-86.
5. Dvir-Szternfeld R, Castellani G, Arad M, Cahalon L, Colaiuta SP, Keren-Shaul H, Croese T, Burgaletto
C, Baruch K, Ulland T, Colonna M, Weiner A, Amit I, Schwartz M. 2022. Alzheimer’s disease
modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in
mouse model of amyloidosis. Nature Aging 2: 60-73 (citations:17).
6. Ben-Yehuda H, Arad M, Peralta Ramos JM, Sharon E, Castellani G, Ferrera S, Cahalon L, Colaiuta SP,
Salame TM, Schwartz M. 2021. Key role of the CCR2-CCL2 axis in disease modification in a mouse
model of tauopathy. Mol Neurodegeneration 16: 39. (citations:20).
7. Cohen M, Giladi A, Raposo C, Zada M, Li B, Ruckh J, Deczkowska A, Mohar B, Shechter R, Lichtenstein
RG, Amit I, Schwartz M. 2021. Meningeal lymphoid structures are activated under acute and chronic
spinal cord pathologies. Life Sci Alliance 4: e202000907.
8. Habib N, McCabe C, Medina S, Varshavsky M, Kitsberg D, Dvir-Szternfeld R, Green G, Dionne D,
Nguyen L, Marshall JL, Chen F, Zhang F, Kaplan T, Regev A, Schwartz M. 2020. Disease- associated
astrocytes in Alzheimer’s disease and aging. Nat Neurosci 23: 701-6. (citations:617).
9. Ben-Yehuda H, Matcovitch-Natan O, Kertser A, Spinrad A, Prinz M, Amit I, Schwartz M. 2020.
Maternal Type-I interferon signaling adversely affects the microglia and the behavior of the offspring
accompanied by increased sensitivity to stress. Mol Psychiatry 25: 1050-67 (Cover page).
10. Kertser A,Baruch K, Deczkowska A,Weiner A,Croese T, Kenigsbuch M,CooperI, Tsoory M,Ben- Hamo
S, Amit I, Schwartz M. 2019. Corticosteroid signaling at the brain-immune interface impedes coping with
severe psychological stress. Sci Adv 5: eaav4111. (citations:32).
11. Rosenzweig N, Dvir-Sternfeld R, Tsitsou-Kampeli A, Keren-Shaul H, Ben-Yehuda H, Weill-Raynal P,
Cahalon L, Kertser A, Baruch K, Amit I, Weiner A, Schwartz M. 2019. PD-1/PD-L1 checkpoint blockade
harnesses monocyte-derived macrophages to combat cognitive impairment in a mouse model of tauassociated dementia. Nat Commun. 10: 465. (citations:141).
12. Deczkowska A, Matcovitch-Natan O, Tsitsou-Kampeli A, Ben-Hamo S, Dvir-Szternfeld R, Spinrad A,
Singer O, David E, Winter RD, Smith KL, Kertser A, Baruch K, Rosenzweig N, Terem A, Prinz M,
Villeda S, Citri A, Amit I, Schwartz M. 2017. Mef2C restrains the microglial inflammatory response and
is lost in brain ageing in an IFN-I-dependent manner. Nat Commun 8: 717. (citations:212).
13. Cohen M, Ben-Yehuda H, Porat Z, Raposo C, Gordon S, Schwartz M. 2017. Newly formed endothelial
2
cells regulate myeloid cell activity following spinal cord injury via expression of CD200 ligand. J
Neurosci 37: 972-85.

Wei Jiang | Cognitive and neuropathology | Women Researcher Award

Posted on by sciencefather

 Dr. Wei Jiang | Cognitive and neuropathology | Women Researcher Award

Medical University of South Carolina , United States

Her academic focus includes microbiome, B cell/autoantibody interactions, and disease pathogenesis, with particular emphasis on HIV, addictive drugs, and systemic lupus erythematosus (SLE). She is involved in several clinical and translational research projects, including R01DA059854 (Jiang & Sheng), investigating the impacts of drug abuse on autoantibodies and immune reconstitution in HIV. She also works on CSRD Merit I01 CX002422, exploring B cell-mediated immunological failure in HIV-infected individuals on antiretroviral therapy. Additionally, she contributes to NIDA-funded studies, such as R01DA055523, examining the oral microbiome’s effect on cognition in HIV-infected cannabis users, and R01DA059538, investigating HIV persistence in cocaine users. Furthermore, she collaborates on a Translational Science Award project exploring the oral microbiome’s impact on cognition in Alzheimer’s disease.

 

 

Profile

Education:

She earned her M.S. in Epidemiology and Biostatistics from Case Western Reserve University, Medical School, Cleveland, USA, in 2012. Prior to that, she completed a Postdoctoral fellowship at Case Western Reserve University, Medical School, Cleveland, USA, in 2008. She holds an M.S. in Immunology from Capital Medical University, Beijing, China, which she completed in 2001. She also received her M.D. in Internal Medicine from Capital Medical University, Beijing, China, in 1997.

BRIEF RESEARCH INTEREST STATEMENT:

She has 8 years of clinical experience in infectious diseases and 22 years of translational research experience in disease immunopathogenesis. As a corresponding author, she has published 52 peer-reviewed articles on microbiome and disease immunopathogenesis in high-profile journals like Microbiome, Arthritis & Rheumatology, J Autoimmunity, and EbioMedicine, bringing her total number of peer-reviewed publications to 101. As a physician-scientist, she has served as Principal Investigator on five R01 grants from NIAID or NIDA, along with a VA clinical merit grant, focusing on microbiomes, drug abuse, autoimmunity, and HIV immunopathogenesis. Her research primarily focuses on two major areas. The first is understanding the role of B cell perturbation and autoantibodies in disease pathogenesis, particularly in HIV and SLE. In 2017, her team first determined that autoimmunity impacts antiretroviral therapy outcomes in HIV without inducing autoimmune disease. This concept was later corroborated in studies on COVID-19. Her team is currently developing monoclonal autoantibodies and inhibitors to prevent anti-CD4 autoantibody binding, aiming to improve CD4+ T cell recovery and reduce morbidity in HIV patients. The second area of focus is the role of microbiomes in disease pathogenesis, including HIV, SLE, and drug abuse. She has identified the impact of disease-associated pathobionts on immune perturbations and disease progression, with findings validated in animal models. Her microbiome research is supported by R01DA055523.

TRAINING, PROFESSIONAL APPOINTMENTS

She currently serves on the Appointment, Promotion & Tenure (APT) committee in the Department of Microbiology and Immunology at the Medical University of South Carolina, a position she has held since 2024. She was promoted to Full Professor with tenure in the Department of Microbiology and Immunology, Division of Infectious Diseases, Department of Medicine at the same institution in 2023. She has been a Faculty Senator for the College of Medicine and a Research Health Scientist at the Ralph H. Johnson VA Medical Center since 2022. Additionally, she is a member of the Translational Science Laboratory IAC (2020-2022) and the MUSC College’s Curriculum Committee (2019-Present). She has held various positions at MUSC, including Associate Professor (2018-2022) and Assistant Professor (2012-2018) in the Department of Microbiology and Immunology. Since 2018, she has been a member of the Hollings Cancer Center at MUSC and has served on the award committee for the Advancement, Recruitment, and Retention of Women in Science. Her academic career began as an Instructor (2008-2012) and Research Associate (2002-2008) at Case Western Reserve University School of Medicine in Cleveland, OH.

AWARDS

She received her Chinese Board of Internal Medicine certification in Infectious Diseases in July 1997 and was certified as an Attending Medical Doctor in Infectious Diseases in November 1999 (No: 10203C089758). In July 1997, she also earned a Teacher Qualification from the Educational Institute, National Educational Committee in China (No: 971100071069382). Her licensure is from Beijing, China.

She has received several awards throughout her career, including the Laboratory Travel Grant from the American Association of Immunologists (AAI) in 2019, the MUSC High Impact Research Publication Award in 2019, and multiple travel grants from AAI for various international immunology congresses. She was awarded the Early Career Faculty Travel Grant by AAI and ECI in 2018 and 2017, and received the Travel Award and HIV Section Chair recognition at the 2016 International Congress of Immunology. In 2015, she was honored with the MUSC Foundation Developing Scholar Award and an Early Career Faculty Travel Grant from AAI. Her earlier achievements include multiple Young Investigator Awards from the 13th and 15th Conferences on Retroviruses and Opportunistic Infections (2006, 2008) and the Keystone Meeting on HIV Pathogenesis (2006, 2008). Additionally, she was recognized as an Outstanding Student Leader for five consecutive years during her medical school years from 1986 to 1991.

OTHER EXPERIENCE AND PROFESSIONAL MEMBERSHIPS

She has held several key professional roles and memberships throughout her career. Since 2024, she has been serving as a mentor for the American Society for Microbiology (ASM) Future Leaders Mentorship Fellowship (FLMF) Program. She is a member of the Society on NeuroImmune Pharmacology 2024 committee and has been a Treasurer Elect for the Association of Chinese Virologists in America from 2022 to 2024. She has been a member of the American Society for Microbiology (ASM) since 2021 and the Infectious Diseases Society of America (IDSA) since 2020. She has also been serving on the Editorial Board of the Journal of Neuroimmune Pharmacology since 2019 and is a member of the Society on NeuroImmune Pharmacology. Additionally, she has been part of the Society of Chinese Bioscientists in America (SCBA) and the American College of Rheumatology since 2018. She has contributed as an award committee member for the Advancement, Recruitment, and Retention of Women in Science at the Medical University of South Carolina since 2017 and is an associate member of the Hollings Cancer Center at MUSC.

She is also an active member of the MUSC Oral Health Center, College of Dental Medicine, and the Medical University of South Carolina College of Graduate Studies. Her previous memberships include being part of the American Association of Immunologists from 2011 to 2021, the Center for AIDS Research from 2008 to 2012, and the AIDS Clinic Trial Group since 2008. Her certification in Chinese Board of Internal Medicine in Infectious Diseases dates back to 1997, along with her teacher qualification from the Educational Institute, National Educational Committee, China.

CURRENT RESEARCH PROJECTS

She is currently leading several impactful research projects. As the Principal Investigator (PI) on R01DA059854 (9/30/2024-5/31/2029), funded by NIDA with a total of $3,924,302, she is studying the impacts of drug abuse-mediated inflammatory perturbations on affinity maturation of anti-CD4 autoantibodies and poor immune reconstitution from ART in HIV. This project aims to understand the role of cocaine in autoimmunity and immune recovery in HIV patients. Her role in this project is as PI (25% effort).

She is also a multiPI on R01DA059538 (9/30/2023-7/31/2028), with a total of $1,724,585 from NIDA, investigating host gene isoforms contributing to HIV persistence in cocaine users. The study focuses on identifying gene isoforms associated with HIV infection in elite controllers and its implications for cocaine users. Her role is PI (25% effort).

In addition, she is the PI on I01CX002422 (3/1/2022-2/28/2026), funded by the VA Medical Center CSRD Merit with a total of $1,195,899. This project examines the mechanism of autoreactive B cell-mediated immunological failure in HIV-infected individuals on antiretroviral therapy despite virologic suppression. She is focused on understanding the molecular mechanisms of anti-CD4 IgG-producing B cells and the pathologic effects of anti-CD4 autoantibodies. Her role is PI with 62.5% effort.

Additionally, she is involved as multiPI on R01DA055523 (9/30/2022-7/31/2027), with a total funding of $1,731,992, where she is working alongside Fitting to investigate the effects of microbiome-related mechanisms on H

 Publication